Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.

Abstract

OBJECTIVE:

To evaluate the changes in aqueous concentrations of inflammatory cytokines and fibrosis-related factors, and to detect the expression of vascular endothelial growth factor (VEGF) and proliferating cells in fibrovascular membranes (FVMs) of patients with proliferative diabetic retinopathy (PDR) after injection of intravitreal bevacizumab (IVB).

METHODS:

Forty-two eyes of 42 patients with PDR, including 28 eyes that received IVB (1.25 mg) 2, 5, and 14 days before pars plana vitrectomy (PPV), and 14 eyes without IVB, were enrolled, in addition to 10 eyes of 10 patients with nondiabetic ocular diseases. Aqueous concentrations of inflammatory cytokines and fibrosis-related factors were analyzed by a multiplex bead assay. Fluorescence immunostaining was performed to examine the expression of VEGF and proliferating cells in the excised epiretinal membranes.

RESULTS:

PDR eyes without IVB had the highest vitreous VEGF levels, and the level was statistically significant compared with that of PDR eyes that received IVB 2 days before surgery, PDR eyes that received IVB 5 days before surgery, and nondiabetic eyes (p = 0.011, p = 0.012, and p < 0.001, respectively). The expression of fibroblastic cells and connective tissue growth factor increased in epiretinal FVMs of the IVB group 21 days after treatment.

CONCLUSIONS:

IVB injection may lead to a decrease in the intraocular concentrations of VEGF after 2-5 days and induce the formation of proliferation after 21 days, which suggests that PPV in PDR patients should take place within 1 week of the administration of preoperative IVB.

• Authors: Jing Feng, Bing Li, Jing Wen, Yanrong Jiang
• Journal: Ophthalmic research (Ophthalmic Res) Vol. 60 Issue 4 Pg. 250-257 ( 2018) ISSN: 1423-0259 [Electronic] Switzerland
• PMID: 30380554 (Publication Type: Journal Article)
• Copyright: © 2018 S. Karger AG, Basel.

Chemical References

• Angiogenesis Inhibitors
• Bevacizumab
• Receptors, Vascular Endothelial Growth Factor

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Bevacizumab (administration & dosage)
• Diabetic Retinopathy (diagnosis, drug therapy, surgery)
• Female
• Fluorescein Angiography
• Follow-Up Studies
• Fundus Oculi
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Ophthalmoscopy
• Preoperative Period
• Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors)
• Time Factors
• Treatment Outcome
• Visual Acuity
• Vitrectomy